AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
December 05, 2019 at 02:11 AM EST
AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a from of ovarian cancer.